BMS, CytomX Therapeutics in expanded broad collaboration

Bristol-Myers Squibb and CytomX Therapeutics, a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, have expanded their 2014 strategic collaboration to discover novel therapies that will include up to eight additional targets using CytomX’s proprietary Probody platform.

Read more